New Concepts in Immunology Relevant to Idiosyncratic Drug Reactions: The “Danger Hypothesis” and Innate Immune System

Landsteiner K., 1935, J. Exp. Med., 61, 10.1084/jem.61.5.643

Park B. K., 1998, Role of drug disposition in drug hypersensitivity:  A chemical, molecular, and clinical perspective. Chem. Res. Toxicol. 11, 969−988

Griem P., 1998, Allergic and autoimmune reactions to xenobiotics:  how do they arise? Immunol. Today 19, 133−141

Parker C. W., 1982, Pharmacol. Rev., 34, 104

Pohl L. R., 1988, Annu. Rev. Pharmacol., 28

Park B. K., 1987, Drug disposition and drug hypersensitivity. Biochem. Pharmacol. 36, 581−590

Uetrecht J. P., 1990, CRC Crit. Rev. Toxicol., 20, 10.3109/10408449009089863

Uetrecht J. P., 1992, Drug Metab. Rev., 24, 10.3109/03602539208996297

Hinson J. A., 1992, Annu. Rev. Pharmacol. Toxicol., 32, 10.1146/annurev.pa.32.040192.002351

Riley R. J., 1995, Clin. Exp. Immunol., 99, 6

Pumford N. R., 1997, Drug Metab. Rev., 29, 57, 10.3109/03602539709037572

Vergani D., 1980, N. Engl. J. Med., 303, 71, 10.1056/NEJM198007103030202

Satoh H., 1989, Proc. Natl. Acad. Sci. U.S.A. 86

Njoku, D., Laster, M. J., Gong, D. H., Eger, E. I., II, Reed, G. F., and Martin, J. L. (1997) Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins:  association between protein acylation and hepatic injury.Anesth. Analg. (N.Y.)84, 173−178.

Uetrecht J. P., 1994, J. Pharmacol. Exp. Ther., 270

Maggs J. L., 1995, J. Pharmacol. Exp. Ther., 275

Mukhtar H., 1989, Drug Metab. Rev., 20, 10.3109/03602538909103568

Jugert F. K., 1994, J. Invest. Dermatol., 102, 10.1111/1523-1747.ep12384210

Baron J. M., 1998, Cytochrome P450 1B1:  a major P450 isoenzyme in human blood monocytes and macrophage subsets. Biochem. Pharmacol. 56, 1105−1110

Spahn-Langguth H., 1992, Drug Metab. Rev., 24, 47

Ju C., 1999, J. Pharmacol. Exp. Ther., 288, 56

Cameron H. A., 1984, Br. Med. J., 289, 10.1136/bmj.289.6442.410

Cohn J. N., 1998, N. Engl. J. Med., 339

Zanni M. P., 1998, J. Clin. Invest., 102, 10.1172/JCI3544

von Greyerz S., 1998, Clin. Exp. Allergy, 28, 11

Weiss M. E., 1988, Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin. Allergy 18, 515−540

Fibbe W. E., 1986, Br. J. Haematol., 64, 10.1111/j.1365-2141.1986.tb04130.x

Pirmohamed M., 1998, Br. Med. J., 316, 10.1136/bmj.316.7140.1295

Gill F. A., 1967, J. Immunol., 98

Warrington R. J., 1979, Can. Med. Assoc. J., 120

Sarkany I., 1981, Int. J. Dermatol., 20, 10.1111/j.1365-4362.1981.tb02024.x

Roujeau J. C., 1985, Int. Arch. Allergy Appl. Immunol., 78, 24, 10.1159/000233856

Dobozy A., 1981, Lymphocyte transformation test in detection of drug hypersensitivity. Clin. Exp. Dermatol. 6, 367−372

Hertl M., 1995, J. Invest. Dermatol., 105, 10.1038/jid.1995.19

Merk H. F., 1997, Int. Arch. Allergy Immunol. 113, 173−176.

Kalish R. S., 1994, J. Allergy Clin. Immunol., 94, 10.1016/0091-6749(94)90202-X

Kalish R. S., 1990, J. Immunol., 145, 10.4049/jimmunol.145.11.3706

Maria V. A., 1997, Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 41, 534−540

Safferman A. Z., 1992, Rechallenge in clozapine-induced agranulocytosis. Lancet 339, 1296−1297

Guest I., 1998, Toxicology, 131, 65, 10.1016/S0300-483X(98)00110-3

Chengappa K. N., 1996, The treatment of clozapine-associated agranulocytosis with granulocyte colony-stimulating factor (G-CSF). Psychopharmacol. Bull. 32, 111−121

Pisciotta V., 1978, Drug-induced agranulocytosis. Drugs 15, 132−143

Satoh H., 1985, J. Pharmacol. Exp. Ther., 233

Gaedigk A., 1994, Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 4, 142−153

Green V. J., 1995, Br. J. Clin. Pharmacol., 39, 10.1111/j.1365-2125.1995.tb04470.x

Leeder J. S., 1998, Epilepsia, 39, S16, 10.1111/j.1528-1157.1998.tb01679.x

Gardner I., 1998, A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Mol. Pharmacol. 53, 999−1008

Batchelor J. R., 1980, Hydralazine-induced systemic lupus erythematosus:  influence of HLA-DR and sex on susceptibility. Lancet 1, 1107−1109

Lieberman J. A., 1990, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch. Gen. Psychiatry 47, 945−948.

Claas F. H., 1992, Drug Saf., 7, 6, 10.2165/00002018-199200071-00004

Matzinger P., 1994, Annu. Rev. Immunol., 12, 10.1146/annurev.iy.12.040194.005015

Miller J. F., 1996, Mechanisms of tolerance to self. Curr. Opin. Immunol. 8, 815−821

Lafferty K. J., 1997, Tolerance:  a case of self/not-self discrimination maintained by clonal deletion? Hum. Immunol. 52, 119−126

Paul W. E., 1999, Fundamental Immunology

Greenfield E. A., 1998, Crit. Rev. Immunol., 18, 10.1615/CritRevImmunol.v18.i5.10

Watts T. H., 1999, T cell costimulatory molecules other than CD28. Curr. Opin. Immunol. 11 (in press)

Matzinger P., 1998, An innate sense of danger. Semin. Immunol. 10, 399−415

Pullen H., 1967, Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis. Lancet 2, 1176−1178

Fischl M. A., 1988, J. Am. Med. Assoc., 259, 10.1001/jama.1988.03720080019021

Levy M., 1997, Drug Saf., 16, 8, 10.2165/00002018-199716010-00001

Ellrodt A. G., 1984, Severe neutropenia associated with sustained-release procainamide. Ann. Intern. Med. 100, 197−201

Meyers D. G., 1985, Am. Heart J., 109, 10.1016/0002-8703(85)90374-6

Richens A., 1994, S37−S40.

Worlledge S. M., 1966, Autoimmune haemolytic anaemia associated with alpha-methyldopa therapy. Lancet 2, 135−139

Worlledge S. M., 1973, Immune drug-induced hemolytic anemias. Semin. Hematol. 10, 327−344

Uetrecht J. P., 1981, Acetylator phenotype and lupus erythematosus. Clin. Pharmacokinet. 6, 118−134

Blomgren S. E., 1972, Am. J. Med., 52, 10.1016/0002-9343(72)90021-6

Janeway C. A., Jr., 1998, J. Immunol., 161

Medzhitov R., 1997, Curr. Opin. Immunol., 9, 9, 10.1016/S0952-7915(97)80152-5

Fearon D. T., 1996, Science, 272, 53, 10.1126/science.272.5258.50

Poccia F., 1998, Innate T-cell immunity to nonpeptidic antigens. Immunol. Today 19, 253−256

Bendelac A., 1997, Curr. Opin. Immunol., 9, 3, 10.1016/S0952-7915(97)80151-3

Fearon D. T., 1997, Seeking wisdom in innate immunity. Nature 388, 323−324

Davies D. M., 1985, Textbook of Adverse Drug Reactions

Romano A., 1998, Clin. Exp. Allergy, 28, 32, 10.1046/j.1365-2222.1998.0280s1032.x

Carr A., 1993, AIDS, 7, 71, 10.1097/00002030-199301000-00010

Albert M. L., 1998, Nature, 392, 89, 10.1038/32183

Martin J. L., 1993, Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase. Hepatology 18, 858−863

Beaune P., 1987, Proc. Natl. Acad. Sci. U.S.A. 84

Cribb A. E., 1997, J. Pharmacol. Exp. Ther., 282

Moudgil K. D., 1994, The T cell repertoire against self-determinants and its involvement in autoimmunity and cancer. Clin. Immunol. Immunopathol. 73, 283−289

Griem P., 1996, Eur. J. Immunol., 26, 10.1002/eji.1830260202

Karlsen A. E., 1998, Semin. Immunol., 10, 34, 10.1006/smim.1997.0102

Uetrecht J. P., 1997, Toxicology, 119, 43, 10.1016/S0300-483X(96)03594-9

Laskin D. L., 1995, Modulation of macrophage functioning abrogates the acute hepatotoxicity of acetaminophen. Hepatology 21, 1045−1050

Badger D. A., 1996, The role of inflammatory cells and cytochrome P450 in the potentiation of CCl4-induced liver injury by a single dose of retinol. Toxicol. Appl. Pharmacol. 141, 507−519

Spielberg S. P., 1981, J. Pharmacol. Exp. Ther., 217

Pirmohamed M., 1991, Br. J. Clin. Pharmacol., 32, 10.1111/j.1365-2125.1991.tb03903.x

Rieder M. J., 1989, Diagnosis of sulfonamide hypersensitivity reactions by in-vitro “rechallenge

Gardner I., 1998, A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes. Mol. Pharmacol. 53, 991−998

Shear N. H., 1988, J. Clin. Invest., 82, 10.1172/JCI113798

Roujeau J. C., 1994, N. Engl. J. Med., 331, 10.1056/NEJM199411103311906